Published in Eur J Gastroenterol Hepatol on June 01, 1999
Identification of beta-subunit of bacterial RNA-polymerase--a non-species-specific bacterial protein--as target of antibodies in primary biliary cirrhosis. Dig Dis Sci (2003) 0.95
Autoantigens in primary biliary cirrhosis. J Clin Pathol (2000) 0.86
Natural history of early primary biliary cirrhosis. Lancet (1996) 3.24
Airway epithelial cells are the site of expression of a mammalian antimicrobial peptide gene. Proc Natl Acad Sci U S A (1993) 2.22
Early induction of humoral and cellular immune responses during experimental Mycobacterium avium subsp. paratuberculosis infection of calves. Infect Immun (2003) 2.12
Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology (1997) 1.94
Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet (1988) 1.90
Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology (1998) 1.84
Incidence and prognostic importance of jaundice after cardiopulmonary bypass surgery. Lancet (1983) 1.78
Accuracy of pedicle screw placement in lumbar fusions by plain radiographs and computed tomography. Spine (Phila Pa 1976) (1995) 1.75
Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res (1996) 1.74
Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut (2000) 1.68
Group B streptococcal colonization patterns in mothers and their infants. J Clin Microbiol (1984) 1.64
Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci U S A (1988) 1.62
Arsenic in Napoleon's wallpaper. Nature (1982) 1.61
Rapid identification of pregnant women heavily colonized with group B streptococci. J Clin Microbiol (1983) 1.61
Aluminum toxicokinetics regarding infant diet and vaccinations. Vaccine (2002) 1.56
Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res (1986) 1.55
Angle-closure glaucoma precipitated by the use of phospholine iodide for esotropia in a child. Br J Ophthalmol (1967) 1.51
Enteric beta-defensin: molecular cloning and characterization of a gene with inducible intestinal epithelial cell expression associated with Cryptosporidium parvum infection. Infect Immun (1998) 1.48
Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol (2011) 1.47
Primary angioplasty reduces risk of myocardial rupture compared to thrombolysis for acute myocardial infarction. Cathet Cardiovasc Diagn (1997) 1.47
Nucleoside analogue therapy in fibrosing cholestatic hepatitis--a case report in an HBsAg positive renal transplant recipient. Liver (1998) 1.45
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study. J Hepatol (2001) 1.42
A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. J Am Coll Cardiol (1996) 1.41
Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology (1981) 1.38
Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol (1999) 1.36
Risk factors and medical follow-up of drug users tested for hepatitis C--can the risk of transmission be reduced? Drug Alcohol Rev (1997) 1.35
Hepatitis C virus antibody. Lancet (1989) 1.33
Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology (1987) 1.32
Hepatitis C virus particles of different density in the blood of chronically infected immunocompetent and immunodeficient patients: Implications for virus clearance by antibody. J Med Virol (2002) 1.32
Scleritis and rheumatoid arthritis. Ann Rheum Dis (1971) 1.31
[Ca2+]i in muscles of malignant hyperthermia susceptible pigs determined in vivo with Ca2+ selective microelectrodes. Muscle Nerve (1986) 1.26
Interferon-gamma and interleukin 4 gene expression in cows infected with Mycobacterium paratuberculosis. Am J Vet Res (1998) 1.25
CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol (2000) 1.21
Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol (1999) 1.20
Low dosage combined adrenaline-guanethidine formulations in the management of chronic simple glaucoma. Trans Ophthalmol Soc U K (1977) 1.20
Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut (1994) 1.18
Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology (1992) 1.18
Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut (1996) 1.17
Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase (E2p): characterization of the main immunogenic region. Proc Natl Acad Sci U S A (1990) 1.17
HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine. Br Med J (1978) 1.15
Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. J Hepatol (2000) 1.13
Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut (2005) 1.11
Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Carcinogenesis (1997) 1.11
"Blow-out" fractures of the orbit: an investigation into their anatomical basis. J Laryngol Otol (1967) 1.11
Primary biliary cirrhosis. Quantitation of autoantibodies to purified mitochondrial enzymes and correlation with disease progression. Gastroenterology (1990) 1.10
Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology (2000) 1.09
Investigation of the role of polymorphisms at the alcohol and aldehyde dehydrogenase loci in genetic predisposition to alcohol-related end-organ damage. Hepatology (1991) 1.09
Elimination of multiple reactions of the Phadebact Streptococcus coagglutination test. J Clin Microbiol (1983) 1.07
Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol (1992) 1.06
Inhibition of transcription of the human c-myc protooncogene by intermolecular triplex. Biochemistry (1998) 1.06
Prospective study of post-transfusion hepatitis after cardiac surgery in a British centre. Br Med J (Clin Res Ed) (1983) 1.05
A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol (1992) 1.03
Primary liver cell cancer in Britain--a viral aetiology? Br Med J (1979) 1.02
Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology (1997) 1.01
The E1 alpha and beta subunits of the pyruvate dehydrogenase complex are M2'd' and M2'e' autoantigens in primary biliary cirrhosis. Clin Sci (Lond) (1989) 1.01
Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age. Age Ageing (1994) 1.00
The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics (1998) 1.00
Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells. Hepatology (1996) 1.00
Human enteric defensin genes: chromosomal map position and a model for possible evolutionary relationships. Genomics (1996) 1.00
Managing chronic hepatitis C acquired through intravenous drug use. QJM (2001) 0.99
T-cell responses to the components of pyruvate dehydrogenase complex in primary biliary cirrhosis. Hepatology (1995) 0.99
Hepatitis C virus density heterogeneity and viral titre in acute and chronic infection: a comparison of immunodeficient and immunocompetent patients. J Hepatol (1996) 0.97
Keratitis due to Mycobacterium chelonei. Tubercle (1978) 0.96
Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology (1989) 0.96
Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics (1999) 0.96
Evaluation of the atypical Pap smear. Am J Obstet Gynecol (1987) 0.95
Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol Biomarkers Prev (1999) 0.94
Characterisation of the reactivity of autoantibodies in primary biliary cirrhosis. FEBS Lett (1989) 0.94
Banana tannin and its reaction with polyethylene glycols. Nature (1965) 0.93
Metal ion binding to adenosine triphosphate. 3. A kinetic analysis. J Am Chem Soc (1968) 0.93
Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis. Immunol Rev (2000) 0.93
Environmental exposures that affect the endocrine system: public health implications. J Toxicol Environ Health B Crit Rev (1998) 0.92
Breakdown of tolerance to pyruvate dehydrogenase complex in experimental autoimmune cholangitis: a mouse model of primary biliary cirrhosis. Hepatology (1999) 0.92
Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study. J Hepatol (1987) 0.92
A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut (1997) 0.92
HLA-DR antigens in primary biliary cirrhosis: lack of association. Gut (1985) 0.92
Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England. J Viral Hepat (2013) 0.91
Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut (1998) 0.91
Alcohol dehydrogenase polymorphisms and predisposition to alcoholic cirrhosis. Hepatology (1993) 0.91
Leishmania major-infected C3H mice treated with anti-IL-12 mAb develop but do not maintain a Th2 response. J Immunol (1997) 0.91
Hepatitis B surface antigen and alpha-fetoprotein secreting human primary liver cell cancer in athymic mice. Gastroenterology (1980) 0.91
Growth characteristics of alpha-foetoprotein-secreting human hepatocellular carcinoma in athymic (nude) mice. Clin Sci (Lond) (1983) 0.91
Effects of prednisolone/azathioprine in chronic hepatitis B viral infection. Gut (1982) 0.90
Primary biliary cirrhosis: clinical and associated autoimmune features and natural history. Clin Liver Dis (1998) 0.90
Polyethylene glycols-tannins interaction in extracting enzymes. Nature (1965) 0.89
Autoantibodies in primary biliary cirrhosis: analysis of reactivity against eukaryotic and prokaryotic 2-oxo acid dehydrogenase complexes. Hepatology (1991) 0.89
Immunohistochemical assessment of hepatitis C virus antigen in cholestatic hepatitis after liver transplantation. J Clin Pathol (2006) 0.89
Cancer risk in primary biliary cirrhosis: a study in northern England. Gut (1999) 0.89
Primary liver cell cancer in autoimmune chronic liver disease. Br Med J (Clin Res Ed) (1981) 0.88
The CLO test in the UK: inappropriate reading and missed results. Eur J Gastroenterol Hepatol (1999) 0.88
Immunological and anti-viral therapy of chronic hepatitis B virus infection. Clin Gastroenterol (1980) 0.88
Human pyruvate dehydrogenase complex as an autoantigen in primary biliary cirrhosis. Clin Sci (Lond) (1993) 0.88
Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment Pharmacol Ther (2009) 0.87
Non-Hodgkin's lymphoma and hepatitis C virus infection. Leuk Lymphoma (1996) 0.87
c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. J Hepatol (1992) 0.87